EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	6203	((544/295,350,405,406,407) or (514/249,255.05,255.06)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/04/03 10:59

Application Number [ ] SEARCH

IDS Flag Clearance for Application 10699804

IDS Information

Content	Mailroom Date	Entry Number	IDS Review	Reviewer
M844	11-04-2003	19	☑	04-03-2006 11:04:39 DRao
M844	04-21-2005	23	☑	04-03-2006 11:04:39 DRao
M844	11-21-2005	24	☑	04-03-2006 11:04:40 DRao

UPDATE

C:\Program Files\Stnexp\Queries\10699804.str



chain nodes :
12 24 30 31 32 33 34 42 43 44 45 46 47 51 52 53 54 55 56 62 63 64 73
74 75 76 77 78 81 89 90 93 95 96 98 100 101 103
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18 19 20 21 22 23 25 26 27
67 68 69 70 71 72 82 83 84 85 86 87
ring/chain nodes :
37
chain bonds :
5-96 7-12 17-98 19-24 30-31 33-34 42-43 43-44 45-46 46-47 51-52 52-53 54-55
55-56 63-64 68-74 71-76 72-73 73-75 73-101 76-77 77-78 81-93 83-103 86-95 87-89
89-90 89-100
ring bonds :
1-2 1-6 2-3 2-11 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 13-14 13-18 14-15 14-23
15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-23 22-25 23-27 25-26 26-27 67-68
67-72 68-69 69-70 70-71 71-72 82-83 82-87 83-84 84-85 85-86 86-87
exact/norm bonds :
2-11 5-96 6-7 7-8 7-12 8-9 9-10 10-11 14-23 17-98 18-19 19-20 19-24 20-21
21-22 22-23 22-25 23-27 25-26 26-27 30-31 33-34 42-43 43-44 45-46 46-47 51-52
52-53 54-55 55-56 71-76 73-75 73-101 81-93 83-103 86-95 89-90 89-100
exact bonds :
63-64 68-74 72-73 76-77 77-78 87-89
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 67-68 67-72 68-69
69-70 70-71 71-72 82-83 82-87 83-84 84-85 85-86 86-87
isolated ring systems :
containing 82 :

G1:[*1],[*2],[*3],[*4]

G2:CN,[*5],[*6],[*7],[*8]

G3:[*9],[*10],[*11],[*12]

G4:Ak,[*5],[*6],[*7],[*8],[*13],[*14]

G5:[*5],[*6],[*8],[*13]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:CLASS 25:Atom 26:Atom 27:Atom 30:CLASS 31:CLASS 32:Atom
33:CLASS 34:Atom 37:CLASS 42:CLASS 43:CLASS 44:Atom 45:CLASS 46:CLASS 47:Atom
51:CLASS 52:CLASS 53:Atom 54:CLASS 55:CLASS 56:Atom 62:Atom 63:CLASS 64:Atom
67:Atom 68:Atom 69:Atom 70:Atom 71:Atom 72:Atom 73:CLASS 74:CLASS 75:CLASS
76:CLASS 77:CLASS 78:Atom 81:CLASS 82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom
89:CLASS 90:CLASS 93:CLASS 95:CLASS 96:CLASS 98:CLASS 100:CLASS 101:CLASS 103:CLASS
Generic attributes :
47:
Saturation : Unsaturated
53:
Saturation : Unsaturated
62:
Saturation : Unsaturated
64:
Saturation : Saturated
78:
Saturation : Unsaturated

Element Count :
Node 32: Limited
N,N1

Node 34: Limited
N,N1

Node 44: Limited
N,N1

Node 56: Limited
N,N1

=>
Uploading C:\Program Files\Stnexp\Queries\10699804.str



chain nodes :
12 24 30 31 32 33 34 42 43 44 45 46 47 51 52 53 54 55 56 62 63
64 73 74 75 76 77 78 81 89 90 93 95 96 98 100 101 103
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18 19 20 21 22 23 25
26 27 67 68 69 70 71 72 82 83 84 85 86 87
ring/chain nodes :
37
chain bonds :
5-96 7-12 17-98 19-24 30-31 33-34 42-43 43-44 45-46 46-47 51-52 52-53
54-55 55-56 63-64 68-74 71-76 72-73 73-75 73-101 76-77 77-78 81-93
83-103 86-95 87-89 89-90 89-100
ring bonds :
1-2 1-6 2-3 2-11 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 13-14 13-18 14-15
14-23 15-16 16-17 17-18 18-19 19-20 20-21 21-22 22-23 22-25 23-27 25-26
26-27 67-68 67-72 68-69 69-70 70-71 71-72 82-83 82-87 83-84 84-85 85-86
86-87
exact/norm bonds :

2-11 5-96 6-7 7-8 7-12 8-9 9-10 10-11 14-23 17-98 18-19 19-20 19-24
20-21 21-22 22-23 22-25 23-27 25-26 26-27 30-31 33-34 42-43 43-44 45-46
46-47 51-52 52-53 54-55 55-56 71-76 73-75 73-101 81-93 83-103 86-95
89-90 89-100
exact bonds :
63-64 68-74 72-73 76-77 77-78 87-89
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 67-68
67-72 68-69 69-70 70-71 71-72 82-83 82-87 83-84 84-85 85-86 86-87
isolated ring systems :
containing 82 :

G1:[*1],[*2],[*3],[*4]

G2:CN,[*5],[*6],[*7],[*8]

G3:[*9],[*10],[*11],[*12]

G4:Ak,[*5],[*6],[*7],[*8],[*13],[*14]

G5:[*5],[*6],[*8],[*13]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:Atom 26:Atom 27:Atom 30:CLASS
31:CLASS 32:Atom 33:CLASS 34:Atom 37:CLASS 42:CLASS 43:CLASS 44:Atom
45:CLASS 46:CLASS 47:Atom 51:CLASS 52:CLASS 53:Atom 54:CLASS 55:CLASS
56:Atom 62:Atom 63:CLASS 64:Atom 67:Atom 68:Atom 69:Atom 70:Atom 71:Atom
72:Atom 73:CLASS 74:CLASS 75:CLASS 76:CLASS 77:CLASS 78:Atom 81:CLASS
82:Atom 83:Atom 84:Atom 85:Atom 86:Atom 87:Atom 89:CLASS 90:CLASS 93:CLASS
95:CLASS 96:CLASS 98:CLASS 100:CLASS 101:CLASS 103:CLASS
Generic attributes :
47:
Saturation : Unsaturated
53:
Saturation : Unsaturated
62:
Saturation : Unsaturated
64:
Saturation : Saturated
78:
Saturation : Unsaturated

Element Count :
Node 32: Limited
N,N1

Node 34: Limited
N,N1

Node 44: Limited
N,N1

Node 56: Limited
N,N1

```
L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 07:53:39 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1687 TO ITERATE

100.0% PROCESSED     1687 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        31277 TO    36203
PROJECTED ANSWERS:               2 TO      124

L2            2 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 08:02:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    32898 TO ITERATE

100.0% PROCESSED    32898 ITERATIONS                               29 ANSWERS
SEARCH TIME: 00.00.01

L3           29 SEA SSS FUL L1

=> => s l3
L4            9 L3

=> d l4 1-9 bib,ab,hitstr
```

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:630607 CAPLUS
DN 144:221542
TI Photoluminescence of some indolylpyrazines
AU Tarkhov, L. I.; Potemkin, V. A.; Kovalev, I. S.; Shul'gin, B. V.
CS GOU VPO Ural. Gos. Tekh. Univ.-UPI, Yekaterinburg, Russia
SO Materialovedenie (2005), (4), 16-22
CODEN: MATEC5
PB OOO Nauka i Tekhnologii
DT Journal
LA Russian
AB The photoluminescence of 20 indolylpyrazine derivs. was studied exptl. and theor. using a BiS algorithm. The relation between the mol. structure and the luminescent wavelength was well predicted by the calcns. and was in good agreement with the exptl. data.
IT **327035-59-6 695207-61-5 695219-42-2**
875932-50-6 875932-51-7 875932-59-5
875932-60-8 875932-61-9
RL: MOA (Modifier or additive use); PRP (Properties); USES (Uses)
(photoluminescence of some indolylpyrazines)
RN 327035-59-6 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-(4-chlorophenyl)-5-(1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 695207-61-5 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-5-(1-methyl-1H-indol-3-yl)-6-(4-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 695219-42-2 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-5-(1-methyl-1H-indol-3-yl)-6-(2-pyridinyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 875932-50-6 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-5-(1H-indol-3-yl)-6-(4-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 875932-51-7 CAPLUS

CN Pyrazinecarboxylic acid, 3-(benzoylamino)-5-(2-methyl-1H-indol-3-yl)-6-(4-methylphenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 875932-59-5 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-(3,4-difluorophenyl)-5-(1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 875932-60-8 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-(4-fluorophenyl)-5-(2-methyl-1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 875932-61-9 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-(4-fluorophenyl)-5-(1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)


F
H
N
N
N
C—OEt
O
Ph—C—NH
O

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:589247 CAPLUS
DN 141:140463
TI Preparation of heterocyclic compounds as selective phosphodiesterase V inhibitors
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
PA Japan
SO U.S. Pat. Appl. Publ., 116 pp., Cont.-in-part of U.S. Ser. No. 258,545.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

Appl. PGPub.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004142930	A1	20040722	US 2003-699804	20031104
	JP 2002012587	A2	20020115	JP 2000-277652	20000913
	JP 3637961	B2	20050413		
	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003229089	A1	20031211	US 2002-258545	20021025
PRAI	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		
	JP 1999-261852	A	19990916		

Parent

(No ODP)

OS MARPAT 141:140463
AB The title compds. (I) [X = CH, N; Y = NH, NR, S, O, CH:N, N:CH, N:N, CH:CHC(:R5)N, CH:C(R5), N:C(R7); R1 = each (un)substituted lower alkoxy, amino, heterocyclyl containing N atom(s), HO, or heterocyclyloxy containing N atom(s), cyano; R2 = lower alkylamino or lower alkoxy each optionally substituted by an (un)substituted aryl, lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), lower alkylamino group substituted by a (un)substituted heterocyclic ring, (un)substituted arylamino; R3 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkyl, lower alkoxy, lower cycloalkoxy, heterocyclyloxy containing N atom(s), or NH2; R4-R7 = each (un)substituted aryl, heterocyclyl containing N atom(s), lower alkoxy, or NH2; R4, R5, R6 or R7 may combine with R3 to form a lactone ring Q or Q1; when X = N, Y = CH:N, or N:CH, R2 = an amino group monosubstituted by an (un)substituted arylmethyl, and R3 = (un)substituted lower alkyl, amino monosubstituted by an (un)substituted heterocyclyl-lower alkyl containing N atom(s) in the ring, heterocyclylamino containing N atom(s) in the ring, or (un)substituted lower cycloalkylamino, R1 = each (un)substituted lower alkoxy, amino, heterocyclyloxy containing N atom(s) in the ring, or cyano group] or pharmacol. acceptable salts thereof are prepared These compds. have excellent selective PDE V inhibitory activity and therefore, are useful as therapeutic or prophylactic drugs for treating various diseases due to functional disorders on cGMP-signaling, such as erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis. Thus, 2-(hydroxymethyl)pyridine was treated with NaH in THF and etherified with 2-chloro-5-(3,4,5-

trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.

IT **330786-12-4P 372115-76-9P 372115-77-0P 726205-56-7P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as selective phosphodiesterase V inhibitors for treating various diseases due to functional disorders on cGMP-signaling)

RN 330786-12-4 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Elected species

RN 372115-76-9 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(2-pyridinylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 372115-77-0 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 726205-56-7 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:434540 CAPLUS
DN 139:6891
TI Preparation of substituted aryl pyrazine derivatives as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders
IN Verhoest, Patrick R.; Hoffman, Robert L.; Corbett, Jeffrey W.; Ennis, Michael D.; Frank, Kristine E.; Fu, Jian-Min
PA Pharmacia & Upjohn Company, USA
SO PCT Int. Appl., 271 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003045924	A1	20030605	WO 2002-US33642	20021115
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2467870	AA	20030605	CA 2002-2467870	20021115
	AU 2002343557	A1	20030610	AU 2002-343557	20021115
	US 2003144297	A1	20030731	US 2002-298193	20021115
	US 6992087	B2	20060131		
	EP 1446387	A1	20040818	EP 2002-780507	20021115
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR				
	BR 2002014309	A	20041013	BR 2002-14309	20021115
	US 2005049257	A1	20050303	US 2004-844004	20040512
PRAI	US 2001-332052P	P	20011121		
	US 2002-358546P	P	20020221		
	US 2002-388285P	P	20020613		
	US 2002-410378P	P	20020913		
	US 2002-298193	A1	20021115		
	WO 2002-US33642	W	20021115		

OS MARPAT 139:6891
AB Substituted aryl 1,4-pyrazine derivs. (shown as I; variables defined below; e.g. 5-(2,4-dichlorophenyl)-N-((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)-3,6-diethylpyrazin-2-amine) and their use in treating anxiety disorders, depression and stress related disorders are disclosed. The binding affinity of I for the corticotropin releasing factor type I receptor expressed as IC50 values generally ranges from .apprx.0.5 nM to .apprx.10 μM; no specific values are given. Although the methods of preparation are not claimed, 131 example prepns. of I and 190 example prepns. of intermediates are included. For I: X = -NR3R4, -OR3, -CR3R5R5, -C(O)R3, -S(O)mR3, - NR3C(O)R4, or -NR3S(O)mR4, m = 0-2; Ar = aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R1, R2, and R5 = halogen, -NO2, -CN, -Ra, -ORa, -S(O)mRa, -NRaRa, -C(O)NRaRa, -C(S)NRaRa, -S(O)mNRaRa, -NRaS(O)mRa, -NRaC(O)ORa, -OC(O)NRaRa, -NRaC(O)NRaRa, -NRaC(S)NRaRa, -C(O)ORa, -C(S)ORa, or -OC(O)ORa. R3 and R4 = Ra or substituted and/or unsubstituted heterocycloalkyl, heteroaryl, aryl, aryl

cycloalkyl, heteroaryl cycloalkyl, aryl heterocycloalkyl, or heteroaryl heterocycloalkyl; Ra = H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl (un)substituted with 1 to 5 of Rt, -ORt, -S(O)mRt, NRtRt, oxo, thione (:S), Ph, heteroaryl, or heterocycloalkyl; Rt = H, halogen, -NO2, -NH2, -OH, -SH, -CN, -C(O)NH2, - C(O)NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)malkyl, SO2NH2, SO2NHalkyl and SO2Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, Ph, benzyl, heteroaryl, or heterocycloalkyl; addnl. details including specifically excluded compds. are given in the claims. Compds. I are also claimed effective for screening ligands for CRF1 receptors and for detecting CRF1 receptors in tissues.

IT **535940-58-0P**, 6-(2,4-Dichlorophenyl)-3-[((1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl)amino]-5-methoxypyrazine-2-carboxamide
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and receptor detection and ligand screening agent; preparation of substituted aryl pyrazine derivs. as CRF1 receptor antagonists useful against anxiety disorders, depression and stress related disorders)

RN 535940-58-0 CAPLUS

CN Pyrazinecarboxamide, 6-(2,4-dichlorophenyl)-3-[[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino]-5-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:900736 CAPLUS
DN 138:4612
TI Preparation of 2-heterocyclyl-4-aminopyrimidine-5-carboxamide and 5-heterocyclyl-3-aminopyrazine-2-carboxamide derivatives as selective inhibitors of phosphodiesterase IV
IN Yamada, Koichiro; Matsumoto, Kenji; Omori, Kenji; Yoshikawa, Kohei
PA Tanabe Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2002338466	A2	20021127	JP 2002-61580	20020307
PRAI JP 2001-73385	A	20010315		

OS MARPAT 138:4612
AB Disclosed is a pharmaceutical composition containing the title compound [I; the ring A = (un)substituted N-containing heterocyclyl; R1 = (un)substituted lower alkyl, NH-Q-R3, NH-R4; wherein R3 = (un)substituted N-containing heterocyclyl; Q = a single bond, lower alkylene; R4 = (un)substituted cycloalkyl; R2 = (un)substituted aryl; one of Y and Z is CH and the other is N] or pharmacol. acceptable salt thereof as the active ingredient for the prevention and/or treatment of impotence, pulmonary hypertension, or diabetic stomach failure or paralysis. Thus, a solution of 2.057 g 2-methylthio-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine was treated with 1.468 g m-chloroperbenzoic acid (80%) at 0° for 30 min, followed by successively adding 0.901 g L-prolinol and 1.33 mL Et3N, and the resulting mixture was allowed to react at 0° for 1 h to give 2.00 g (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-formylpyrimidine (II). A solution of 91.0 mg II in 20 mL THF was reacted with 1.1 mL 1.10 M MeLi/Et2O at -78° for 10 min to give, after treatment with aqueous NaHCO3 and extraction with EtOAc, an EtOAc solution of crude (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-(1-hydroxyethyl)pyrimidine which was stirred with 0.5 g MnO2 at room temperature overnight and then at refluxing temperature for 5 h to give (S)-2-(2-hydroxymethyl-1-pyrrolidinyl)-4-(3-chloro-4-methoxybenzylamino)-5-acetylpyrimidine (III). III and inhibitors N-(2-pyridylmethyl)-2-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine-5-carboxamide showed IC50 of 5.18 and 0.0859 μM, resp., against PDE IV isolated from a dog lung. III in vitro exhibited the relaxant activity on rabbit corpus cavernosum with ED50 of 1 nM.
IT **330784-43-5P**, (S)-2-[N-(2-Pyrimidinylmethyl)carbamoyl]-3-((3-chloro-4-methoxybenzyl)amino)-5-(2-hydroxymethyl-1-pyrrolidinyl)pyrazine
330784-44-6P 330784-45-7P 330785-08-5P
330785-09-6P 330785-10-9P 330785-11-0P
330785-12-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylaminopyrimidinecarboxamide and heterocyclylaminopyrazinecarboxamide derivs. as selective inhibitors of phosphodiesterase IV for prevention and/or treatment of diseases)

RN 330784-43-5 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330784-44-6 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-45-7 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-08-5 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(4-methyl-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-09-6 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-10-9 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330785-11-0 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330785-12-1 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-[(4-methyl-2-morpholinyl)methyl]-(9CI) (CA INDEX NAME)



IT **330786-12-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclylaminopyrimidinecarboxamide and heterocyclylaminopyrazinecarboxamide derivs. as selective inhibitors of phosphodiesterase IV for prevention and/or treatment of diseases)
RN 330786-12-4 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Cl
MeO
MeO
O
H
N
N
N
N
S
OH

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:637504 CAPLUS
DN 137:159373
TI Tablets quickly disintegrated in oral cavity
IN Sugimoto, Masaaki; Murakami, Hideki; Koida, Yoshiyuki
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

Common Assignee

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064119	A1	20020822	WO 2002-JP1140	20020212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2437754	AA	20020822	CA 2002-2437754	20020212
	JP 2002316923	A2	20021031	JP 2002-33547	20020212
	EP 1366760	A1	20031203	EP 2002-711460	20020212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1527701	A	20040908	CN 2002-805070	20020212
	NZ 527585	A	20050429	NZ 2002-527585	20020212
	US 2004109890	A1	20040610	US 2003-468208	20030818
PRAI	JP 2001-38343	A	20010215		
	WO 2002-JP1140	W	20020212		

No ODP

OS MARPAT 137:159373
AB Disclosed are tablets which are quickly disintegrated in the oral cavity without giving any unpleasant taste in taking and quickly absorbed in the digestive tract thereby achieving the drug effect. These tablets contain a drug which is hardly soluble in water under neutral or alkaline conditions but highly soluble in water under acidic conditions with giving an unpleasant taste. These tablets can be produced by blending the drug with a water-soluble acidic substance, coating one or both of them with a water-soluble coating which is insol. in alc. solvents, further adding a water-soluble binder which is soluble in alc. solvents and water-soluble saccharide(s), molding the mixture under low pressure and then treating with an alc. solvent. Fast disintegrating tablets containing a cGMP-specific phosphodiesterase 5 (PDE-5) inhibitor 2-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine-7-yl)-4-(3-chloro-4-methoxybenzylamino)-5-[N-(2-pyrimidinylmethyl)carbamoyl]pyrimidine were prepared
IT **330784-43-5 330784-45-7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fast-disintegrating tablet compns. having taste masking characteristics)
RN 330784-43-5 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330784-45-7 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:816647 CAPLUS
DN 135:357948
TI Preparation of heterocyclic compounds as phosphodiesterase V (PDE V) inhibitors
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 207 pp.
CODEN: PIXXD2
DT Patent
LA Japanese

Appl PCT

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001083460	A1	20011108	WO 2001-JP2034	20010315
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001041142	A5	20011112	AU 2001-41142	20010315
	CA 2407231	AA	20021023	CA 2001-2407231	20010315
	EP 1277741	A1	20030122	EP 2001-912373	20010315
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 522217	A	20040430	NZ 2001-522217	20010315
	CN 1657523	A	20050824	CN 2004-10098098	20010315
	US 2003229089	A1	20031211	US 2002-258545	20021025
	US 2004142930	A1	20040722	US 2003-699804	20031104
PRAI	JP 2000-130371	A	20000428		
	JP 2000-277652	A	20000913		
	WO 2001-JP2034	W	20010315		
	US 2002-258545	A2	20021025		

OS MARPAT 135:357948

AB Compds. of the general formula (I) or pharmacol. acceptable salts thereof [wherein X is :CH or N; Y is NH, NR4, S, O, CH:N, N:CH, N:N, CH:CH, or the like; R1 is lower alkoxy, amino, a nitrogenous heterocyclic group, or a hydroxyl group substituted with a heterocyclic group (wherein each group may be substituted); R2 is either a lower alkylamino or lower alkoxy group which may be substituted with aryl, or a lower alkoxy group substituted with a nitrogenous aromatic heterocyclic group; and R3 is aryl, a nitrogenous heterocyclic group, lower alkyl, lower alkoxy, lower cycloalkoxy, a hydroxyl group substituted with a nitrogenous heterocyclic group, or amino (wherein each group may be substituted), or alternatively, R3 and the substituent of Y may be united to form a lactone ring] or pharmacol. acceptable salts thereof are prepared These compds. exhibit excellent PDE V inhibitory activity and are useful as preventive or therapeutic agents for various diseases due to dysfunction of the signal transduction through cGMP, in particular impotence, pulmonary hypertension, and diabetic renal failure paralysis (no data). Thus, 2-(hydroxymethyl)pyridine was treated wit NaH in THF at room temperature for 30 min and then condensed with 2-chloro-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine (preparation given) in THF at room temperature for 1 h

to give 2-(2-pyridylmethoxy)-5-(3,4,5-trimethoxyphenylcarbonyl)-4-(3-chloro-4-methoxybenzylamino)pyrimidine.

IT **330784-43-5P 330786-12-4P 372115-76-9P 372115-77-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as phosphodiesterase V inhibitors preventive or therapeutic agents for various diseases due to dysfunction of signal transduction through cGMP)

RN 330784-43-5 CAPLUS

CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330786-12-4 CAPLUS

CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Elected species.

RN 372115-76-9 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(2-pyridinylmethoxy)-, methyl ester (9CI) (CA INDEX NAME)



RN 372115-77-0 CAPLUS
CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2001:208252 CAPLUS
DN 134:252363
TI Preparation and effect of nitrogen-containing-six-membered aromatic compounds as PDE V activity inhibitors
IN Yamada, Koichiro; Matsuki, Kenji; Omori, Kenji; Kikkawa, Kohei
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019802	A1	20010322	WO 2000-JP6258	20000913
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2383466	AA	20010322	CA 2000-2383466	20000913
	AU 2000073118	A5	20010417	AU 2000-73118	20000913
	AU 767558	B2	20031113		
	BR 2000014526	A	20020618	BR 2000-14526	20000913
	TR 200200701	T2	20020621	TR 2002-200200701	20000913
	EP 1219609	A1	20020703	EP 2000-960979	20000913
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	RU 2233273	C2	20040727	RU 2002-109792	20000913
	US 2003032647	A1	20030213	US 2001-925892	20010810
	US 6656935	B2	20031202		
	ZA 2002001499	A	20020902	ZA 2002-1499	20020222
	NO 2002001308	A	20020424	NO 2002-1308	20020315
	BG 106566	A	20030228	BG 2002-106566	20020402
	US 2003229095	A1	20031211	US 2003-426884	20030501
	US 6797709	B2	20040928		
PRAI	JP 1999-261852	A	19990916		
	JP 2000-130371	A	20000428		
	WO 2000-JP6258	W	20000913		
	US 2001-925892	A3	20010810		

OS MARPAT 134:252363
AB Title compds. [I; A is an optionally substituted nitrogenous heterocyclic group; R1 is optionally substituted lower alkyl, NHQR3 (wherein R3 is an optionally substituted nitrogenous heterocyclic group; and Q is lower alkylene or a single bond), or NHR4 (wherein R4 is optionally substituted cycloalkyl); R2 is optionally substituted aryl; and either of Y and Z is CH and the other is N], pharmacol. acceptable salts are prepared and are exhibiting an excellent selective inhibitory activity against PDE V and being useful as preventive or therapeutic drugs for erectile dysfunction (no data). Thus, the title compound II was prepared
IT **330786-12-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and effect of heteroarom. compds. as PDE V activity inhibitors)
RN 330786-12-4 CAPLUS

CN Pyrazinecarboxylic acid, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **330784-43-5P 330784-44-6P 330784-45-7P**
330785-08-5P 330785-09-6P 330785-10-9P
330785-11-0P 330785-12-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and effect of heteroarom. compds. as PDE V activity inhibitors)

RN 330784-43-5 CAPLUS

CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330784-44-6 CAPLUS

CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA

INDEX NAME)



RN 330784-45-7 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-08-5 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(4-methyl-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-09-6 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-5-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-10-9 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330785-11-0 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330785-12-1 CAPLUS
CN Pyrazinecarboxamide, 3-[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-[(4-methyl-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:900621 CAPLUS
DN 134:56683
TI Preparation of nitrogen-containing heterocyclic derivatives as remedies for complications of diabetes based on protein kinase C inhibition
IN Suzuki, Takayuki; Onda, Kenichi; Murakami, Takeshi; Negoro, Kenji; Yahiro, Kiyoshi; Maruyama, Tatsuya; Shimaya, Akiyoshi; Ohta, Mitsuaki
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000076980	A1	20001221	WO 2000-JP3768	20000609

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI JP 1999-163344 A 19990610
JP 1999-165217 A 19990611
OS MARPAT 134:56683
AB The title compds. I [Y and X together are N:N, C(R4):N, etc.; D = (un)substituted aryl, etc.; R1 = (un)substituted heteroaryl, etc.; A1, A2 = (un)substituted alkylene, etc.; R2, R3, R4 = H, OH, etc.; or R1A2NR3 = (un)substituted heteroaryl] are prepared The title compound II in vitro showed IC50 of 0.0049 μmol against protein kinase C.
IT **313338-72-6P 313338-93-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nitrogen-containing heterocyclic derivs. as remedies for complications of diabetes)
RN 313338-72-6 CAPLUS
CN Pyrazinecarboxamide, 5-[[2-(dimethylamino)ethyl]amino]-3-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 313338-93-1 CAPLUS
CN Pyrazinecarboxamide, 5-[[2-(dimethylamino)ethyl]amino]-6-phenyl-3-(phenylamino)- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:876627 CAPLUS
DN 134:193276
TI Direct introduction of indoles into 2-aminopyrazine 1-oxides
AU Kovalev, Igor S.; Kozhevnikov, Dmitry N.; Rusinov, Vladimir L.; Chupakhin, Oleg N.; Raikov, Dmitry V.; Pustovarov, Vladimir A.; Shul'gin, Boris V.
CS Department of Organic Chemistry, Urals State Technical University, Yekaterinburg, 620002, Russia
SO Mendeleev Communications (2000), (6), 229-230
CODEN: MENCEX; ISSN: 0959-9436
PB Russian Academy of Sciences
DT Journal
LA English
OS CASREACT 134:193276
AB The synthesis of 6-indol-3-yl-2-pyrazinamines, analogs of the bioluminescent natural product Cypridina etioluciferamine, with enhanced photoluminescent properties, is reported.
IT **327035-59-6P 327035-62-1P 327035-65-4P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and photoluminescence)
RN 327035-59-6 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-(4-chlorophenyl)-5-(1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 327035-62-1 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-(4-chlorophenyl)-5-(1-methyl-1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 327035-65-4 CAPLUS
CN Pyrazinecarboxylic acid, 3-(benzoylamino)-6-(4-chlorophenyl)-5-(2-methyl-1H-indol-3-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d his

     (FILE 'HOME' ENTERED AT 07:52:54 ON 03 APR 2006)

     FILE 'REGISTRY' ENTERED AT 07:52:59 ON 03 APR 2006
L1              STRUCTURE UPLOADED
L2            2 S L1 SSS SAM
L3           29 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 08:02:30 ON 03 APR 2006
L4            9 S L3

     FILE 'CAOLD' ENTERED AT 08:02:58 ON 03 APR 2006

=> s l3
L5            0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44     220.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -6.75

STN INTERNATIONAL LOGOFF AT 08:03:10 ON 03 APR 2006
```